The Release Study

• Study Objective:

• To evaluate the efficacy of an extended-release version of lanreotide in providing steady medication levels while reducing the frequency of injections.

• Understanding Acromegaly:
• Lanreotide helps regulate hormones, including human growth hormone, making it beneficial for treating conditions like acromegaly, which is caused by excess hormones.
  
  
• Importance of Treatment:
• Long-term treatment is often necessary for these hormonal conditions, and an extended-release formulation can potentially improve patient adherence and outcomes.
  
  
• Clinical Trial Details:
• The trial focuses on assessing the extended-release lanreotide's ability to maintain drug effectiveness with less frequent dosing.
• An independent ethics committee has approved this clinical trial.
• Participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!